Binge eating in pre-clinical models

Pharmacol Rep. 2015 Jun;67(3):504-12. doi: 10.1016/j.pharep.2014.11.012. Epub 2014 Dec 8.

Abstract

Obesity is a globally widespread disease. Approximately 35% of world population has the problem of inappropriate body weight due to sedentary lifestyle, excessive food consumption and the lack of physical activity. In the course of many years, several pharmacological anti-obesity drugs have been discovered. Most of them, however, possess severe side effects. Recent findings suggest that disturbed functioning of the reward system can be involved in the development of obesity. The data coming from clinical and animal studies provide new evidence that links excessive food consumption with compulsive behavior that can lead to binge eating disease occurrence. In this review we discuss most commonly used animal models of binge eating such as restriction/refeeding, limited access and stress schedule model, and related to them neurobiological findings as well. We also present new, anti-obesity drugs, which are characterized by central mechanism of action.

Keywords: Binge eating; Obesity; Pharmacotherapy; Reward system.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Obesity Agents / pharmacology
  • Anti-Obesity Agents / therapeutic use*
  • Binge-Eating Disorder / drug therapy*
  • Binge-Eating Disorder / metabolism
  • Binge-Eating Disorder / psychology*
  • Body Weight / drug effects
  • Body Weight / physiology
  • Disease Models, Animal*
  • Humans
  • Obesity / drug therapy
  • Obesity / metabolism
  • Obesity / psychology

Substances

  • Anti-Obesity Agents